shift from symptom-oriented to preventionoriented care delivery has accelerated the development of mobile health (mHealth) technologies and is thought to radically transform health care delivery. 1 Smartphone adoption is increasing rapidly, with 64% of Americans using smartphones in 2014 of which 62% used their telephones to look up health information. 2 Many health apps are available, most of which provide health information or support data collection. 3 For patients with inflammatory bowel diseases (IBD), apps are available that assist in tracking symptoms, logging meals, and managing medications. 4, 5 These apps can create reports for providers but do not allow for realtime interactions between patient and provider.
Self-monitoring and self-management for chronic diseases is widely practiced in diabetes care 6 and anticoagulation therapy. 7 Additionally, e-technologies for symptom reporting between patients and providers are increasingly used in chronic diseases. 8 Several systems for online symptom reporting and disease management have been developed for IBD. In the Danish ConstantCare web system, patients with ulcerative colitis (UC) filled out a clinical symptom score and logged fecal calprotectin levels weekly; based on these scores the system made real-time recommendations for adjusting mesalamine Q7 dosing. This approach was shown to empower patients and decrease relapse duration. 9, 10 Similarly, individualization of infliximab dosing in patients with Crohn's disease (CD) was reported to be practical and feasible. 11 A study evaluating another home tele-management system in UC (UC-HAT) did not show significant differences in disease activity and quality of life between users and control subjects, and more than one-third of the patients discontinued participation. 12 An ongoing multicenter randomized controlled trial is testing the use of a mobile tele-management system using text messaging in IBD. This system sends personalized alerts and educational texts, and assesses symptoms and side effects, based on which treatment can be modified. 13 Patient-reported outcomes (PROs) are increasingly used to evaluate health status, and the importance of PROs in outcome measurement, symptom management, and quality improvement efforts is increasingly recognized.
14 Furthermore, the use of PROs as primary outcome measures for evaluating effectiveness of IBD interventions is progressively supported by the Food and Drug Administration. 15 Therefore, PROs are promising for use in mHealth apps. An example is the Health-PROMISE app, which tracks patient-reported quality of life scores in patients with IBD and provides decision support to physicians. 16 However, accurate e-monitoring tools for disease activity in IBD are yet to be developed. Previous efforts have aimed to develop PRO questionnaires by adjusting existing scores. [17] [18] [19] We aimed to identify the most optimal PRO score to use on an IBD disease-monitoring app. The best PROs were selected from an exhaustive list of PROs in a prospective cohort of patients with IBD. Subsequently, the developed scores were tested prospectively in an independent cohort at 3 independent IBD centers.
Methods

Design
We performed a prospective, observational study that aimed to develop and validate an mHealth index (mHI) for CD and UC that accurately monitors IBD disease activity using PROs. The study consisted of 2 phases: a development phase and a validation phase. During the development phase the mHIs were developed using collected PROs and clinical disease activity indices. During the validation phase the developed mHIs were validated in an independent cohort.
Population
Development phase. Patients with IBD were identified during clinic visits between May 2013 and January 2014 at the University of California, Los Angeles (UCLA) Center for IBD. Patients with esophageal or anal CD involvement alone, patients with a pouch or stoma, and pregnant women were excluded. Eligible patients filled out disease-specific questionnaires assessing PROs of most common clinical disease activity indices: partial Mayo (pMayo), simple clinical colitis activity index (SCCAI), and modified Truelove and Witts index for UC; Harvey Bradshaw index (HBI) and CD activity index (CDAI) including a 7-day diary before the visit (Supplementary Figure 1) for CD. Additionally, patients were asked to assess their symptoms and perceived disease activity using visual analogue scales (VAS). The PROs were categorized into 10 domains: stool frequency, abdominal pain, general well-being, urgency, stool consistency, rectal bleeding, fever, anorexia, nausea/vomiting, and perceived disease activity (Table 1) .
During clinic visits, vital signs were measured and physicians collected the physician-reported outcomes required for the clinical disease activity indices (Table 1) . Hemoglobin (Hgb), hematocrit, white blood cell count, platelets, albumin, C-reactive protein, and erythrocyte sedimentation rate were requested. Furthermore, stool testing for calprotectin was requested either at the patient's preferred laboratory or using a free stool kit (Genova Diagnostics, Asheville, NC) picked up at the patient's home. A dedicated study nurse (E.K.I
Q8
.) followed up with patients via telephone or e-mail to ensure laboratory and stool tests were performed.
Validation phase. Eligible patients with IBD were identified during clinic and endoscopy visits between 175  176  177  178  179  180  181  182  183  184  185  186  187  188  189  190  191  192  193  194  195  196  197  198  199  200  201  202  203  204  205  206  207  208  209  210  211  212  213  214  215  216  217  218  219  220  221  222  223  224  225  226  227  228  229  230  231  232 April 2014 and March 2015 in 3 tertiary IBD referral centers (UCLA; University of California, Irvine [UCI]; and Leiden University Medical Center [LUMC], the Netherlands). Patients who participated in the development phase of the study were excluded. For patients with CD, the developed mHI-CD and HBI were completed during clinic visits; during endoscopic visits, the simple endoscopic score for CD (SES-CD) was additionally completed. For patients with UC, the mHI-UC and pMayo were collected during clinic visits, and the Mayo endoscopic subscore was additionally obtained during endoscopic visits. Patients at LUMC completed a Dutch version of the mHI-CD and mHI-UC. After translation to Dutch, the questionnaires were translated back to English by an independent translator; the Dutch questionnaire was then revised and retested. To assess sensitivity of the mHI to detect changes in clinical disease activity, a subset of patients was included a second time during scheduled follow-up visits. To assess testtest reliability, a subset of UCLA patients was asked to complete a second questionnaire at home after their clinic visit.
Definitions
For CD, clinical disease activity was defined as an HBI >4 or a CDAI >150. A change of 3 in HBI was considered a clinically relevant change. 20 Endoscopic disease activity was defined as an SES-CD >3. For UC, clinical disease activity was defined as a pMayo >2, a PTI Q9 >3, or an SCCAI >2. A change of 3 in the pMayo was considered a clinically relevant change. 18 Endoscopic disease activity was defined as a Mayo endoscopic subscore >1.
Ethical Considerations
All patients consented to participate in this study. This study was approved by the institutional review 
Statistical Analysis
Descriptive statistics were used for clinical characteristics and demographic information. Numeric values are presented as mean and standard deviation or median and range. SAS version 9.2 (SAS Institute, Cary, NC) was used for statistical analyses.
Development phase. Univariate logistic regression was performed using disease activity (HBI >4 for CD or pMayo >2 for UC) as the dependent variable and the PROs as independent variables. For each of the PROs, different cutoffs were used, which roughly created linear associations between the groups and the chance of active disease. Because different PROs represented the same domain (Table 1 ), the variables with the highest Wald chi-square value for predicting clinical disease activity were selected within each domain for inclusion in the multivariate logistic regression models. If 2 variables within the same domain had a similar predictive value (difference between Wald chi-square values <0.5), both were tried in separate models unless the question type was less preferable. Because of usability on a mobile application VAS, yes/no, or numeric questions were preferred over categorical questions; within those, questions with less response options were preferred. Variables with a P value >.1 in the univariate analysis were omitted from subsequent analyses. Stepwise forward multivariate logistic regression was performed with clinical disease activity as the dependent variable and the selected PROs as independent variables. A significance level of P < .1 was required for entry in the model and a significance level of P < .1 to stay in the model. Several models were performed using different clinical disease activity indices to define clinical disease activity as the dependent variable.
Composite scores were created using the regression coefficients of independent predictors in the multivariate model. Spearman correlation coefficients were estimated between the newly developed mHIs and clinical disease activity indices. Receiver operating characteristic (ROC) curves were used to assess the capability of the mHI to discriminate active versus nonactive disease using different clinical disease activity indices, and the areas under the curves (AUC) were calculated. The composite score with overall highest AUC using different gold standards was selected.
Because the main aim of the developed score was to identify patients at risk for active disease, we defined the optimal cutoff for disease activity as a negative predictive value (NPV) of 95% and a sensitivity of 85% while maintaining maximum specificity. The overall prevalence of active disease was estimated at 22% based on cross-sectional cohort data from UCLA.
Validation phase. To validate the mHI against clinical and endoscopic disease activity indices, the mHI-UC was compared with the pMayo and the endoscopic subscore of the Mayo; the mHI-CD was compared with the HBI and SES-CD. Spearman correlation coefficients between the scores were calculated and ROC curves to assess the ability to predict clinical and endoscopic disease activity were generated. To assess sensitivity to change, we compared patients who clinically improved, remained stable, and deteriorated. A Kruskal-Wallis test was used to compare groups. Test-retest reliability was assessed by the intraclass correlation coefficient. The performance of the VAS for patient-reported disease activity (DA-VAS) as single predictor for clinical and endoscopic disease activity also was assessed.
Results
Development Phase
In total, 219 patients (110 CD and 109 UC) were included in the development phase of the study ( Figure 1A , Table 2 ). In 108 out of 110 patients with CD the HBI was calculated, whereas the CDAI could only be calculated in 93 out of 110. The pMayo, SCCAI, and modified Truelove and Witts index were calculated in all patients with UC. Complete laboratory and stool tests were obtained from only 48% of patients. Despite intensive follow-up by a dedicated research nurse (E.K.I.), 39% of patients did not perform stool testing and 13% did not have laboratory values drawn. Additionally, 14% of patients had blood drawn, but laboratory sets were incomplete because of protocol deviations.
Univariate logistic regression was performed for PROs and blood and stool tests (Supplementary Tables 1  and 2 ). Stool frequency, abdominal pain, general wellbeing, urgency, and patient-reported disease activity were all strong predictors for clinical disease activity in both CD and UC (P < .0001). Incontinence was only present in 3% of patients and did not predict disease activity in either CD (P ¼ .54) or UC (P ¼ .99). In CD the use of antidiarrheals was predictive for disease activity (P ¼ .019) but not in UC (P ¼ .96), whereas the VAS assessing frequency of antidiarrheal use was a predictor for neither CD (P ¼ 1.00) nor UC (P ¼ .26). Rectal bleeding was a predictor for disease activity in both UC (P < .0001) and CD (P ¼ .019). Anorexia was predictive in both CD (P ¼ .019) and UC (P ¼ .0025), whereas nausea and vomiting predicted only CD disease activity (P ¼ .035) and not UC disease activity (P ¼ .14). High Creactive protein (P ¼ .0009), high erythrocyte sedimentation rate (P ¼ .0022), low Hgb (P ¼ .022), and low albumin (0.034) were predictors for clinical disease activity in CD. High calprotectin was not a significant predictor for CD disease activity (P ¼ .054), although calprotectin as continuous variable had predictive value 349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376  377  378  379  380  381  382  383  384  385  386  387  388  389  390  391  392  393  394  395  396  397  398  399  400  401  402  403  404  405  406   407  408  409  410  411  412  413  414  415  416  417  418  419  420  421  422  423  424  425  426  427  428  429  430  431  432  433  434  435  436  437  438  439  440  441  442  443  444  445  446  447  448  449  450  451  452  453  454  455  456  457  458  459  460  461  462  463  464 (P ¼ .011). Low platelets (P ¼ .98), low hematocrit (P ¼ .28), and high white blood cell (P ¼ .11) were not predictive in CD (Supplementary Table 1 ). In UC high C-reactive protein (P ¼ .0067), high calprotectin (P ¼ .022), high white blood cell (0.013), high erythrocyte sedimentation rate (P ¼ .028), and low hematocrit (P ¼ .0047) were all predictive for clinical disease activity. Low albumin (P ¼ .98) was not predictive for clinical activity in UC, although albumin as continuous variable was (P ¼ .02). Low platelets (P ¼ .99) and low Hgb (P ¼ .13) were not predictive for disease activity in UC, whereas Hgb as continuous variable (P ¼ .032) was (Supplementary Table 2 ).
The most representative PROs were selected for inclusion in the multivariate regression model (Supplementary Tables 1 and 2 ). Because of low completion rates of laboratory testing despite intensive follow-up, laboratory tests were initially excluded from the multivariate analysis and score development. In CD, 4 composite scores were developed (Supplementary Table 3 ); in UC, 11 composite scores were evaluated (Supplementary Table 4 ). Addition of laboratory variables to the selected models decreased the sample size and therefore the power of the regression models; addition of the laboratory variables to the model did not result in inclusion of these variables in the models, 465  466  467  468  469  470  471  472  473  474  475  476  477  478  479  480  481  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502  503  504  505  506  507  508  509  510  511  512  513  514  515  516  517  518  519  520  521  522   523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580 because they did not reach the required significance level of P < .1 for entry in the model. For CD the selected composite score (Table 3) had an AUC of >0.95 for predicting clinical disease activity, using both CDAI and HBI as gold standards (0.951 and 0.963, respectively). The Spearman correlation coefficients were 0.837 and 0.830, respectively (Supplementary Table 3 ). The optimal cutoff for the mHI-CD to predict clinical disease activity was set at 5.5, resulting in an NPV of 96%, positive predictive value (PPV) of 63%, sensitivity of 88%, and specificity of 85%. For UC the selected composite score (Table 3) had an AUC of >0.91 to predict disease activity using pMayo, SCCAI, and modified Truelove and Witts index as gold standards (0.960, 0.915, and 0.913, respectively). The Spearman correlation coefficients were 0.820, 0.832, and 0.790, respectively (Supplementary Table 4 ). The optimal cutoff for the mHI-UC to predict clinical disease activity was set at 4.99, resulting in an NPV of 97%, PPV of 72%, sensitivity of 89%, and specificity of 90%.
Validation Phase
A total of 301 patients with CD (UCLA, n ¼ 127; UCI, n ¼ 82; LUMC, n ¼ 92) and 265 patients with UC (UCLA, n ¼ 119; UCI, n ¼ 67; LUMC, n ¼ 79) were analyzed in the validation phase ( Figure 1B , Table 2 ). For CD the Spearman correlation coefficient was 0.75 (P < .0001) between HBI and mHI-CD, the AUC of the ROC for predicting clinical disease activity was 0.90, and a sensitivity of 94% and specificity of 67% were achieved using a cutoff of 5.5 (Figures 2A and 2B) . To achieve the optimal NPV of 95% and sensitivity of 85%, the cutoff in this cohort would be 6.38, which would result in 85% sensitivity, 80% specificity, 95% NPV, and 55% PPV. The mHI-CD was poorly correlated with the SES-CD (r ¼ .30; P ¼ .0039), with an AUC of 0.63 (Figures 2A and 2C) .
For UC the Spearman correlation coefficient was 0.72 (P < .0001) between pMayo and mHI-UC, the AUC of the ROC for predicting clinical disease activity was 0.91, and a sensitivity of 73% and specificity of 90% specificity were achieved using a cutoff of 4.99 (Figures 2D and 581  582  583  584  585  586  587  588  589  590  591  592  593  594  595  596  597  598  599  600  601  602  603  604  605  606  607  608  609  610  611  612  613  614  615  616  617  618  619  620  621  622  623  624  625  626  627  628  629  630  631  632  633  634  635  636  637  638   639  640  641  642  643  644  645  646  647  648  649  650  651  652  653  654  655  656  657  658  659  660  661  662  663  664  665  666  667  668  669  670  671  672  673  674  675  676  677  678  679  680  681  682  683  684  685  686  687  688  689  690  691  692  693  694  695  696 2E). The optimal cutoff in this cohort would be 3.2, which would result in 85% sensitivity, 80% specificity, 95% NPV, and 55% PPV. The mHI-UC was strongly correlated with the Mayo endoscopic subscore (r ¼ .60; P < .0001), with an AUC of 0.82 ( Figures 2D and 2F ). Sensitivity to change was assessed in a subset of 50 patients with CD and 44 patients with UC. Median time between questionnaires was 46 days (range, 2-352) for CD and 57.5 days (range, 3-275) for UC. Four (8%) patients with CD deteriorated, 31 (62%) had stable disease activity, and 15 (30%) improved. Of the patients with UC, 5 (11%) deteriorated, 27 (61%) remained stable, and 12 (27%) improved. There was a significant difference in mHI between patients who clinically improved, remained stable, or worsened, with either CD (P ¼ .0030) or UC (P ¼ .0025) (Figures 3A and 3C ). Test-retest reliability was assessed in a subset of 40 patients with CD and 37 patients with UC. The median time to second questionnaire completion was 21 hours (range, 7-36) for the mHI-CD and 23 hours (range, 11-144) for the mHI-UC. The intraclass correlation coefficient was 0.94 (confidence limits, 0.89-0.97) for the mHI-CD and 0.94 (confidence limits, 0.89-0.97) for the mHI-UC (Figures 3B and 3D) .
One question in both the mHI-CD and the mHI-UC assessed patient-reported disease activity using a VAS (DA-VAS). In patients with CD (n ¼ 301) the DA-VAS had a Spearman correlation of 0.63 (P < .0001) with the HBI, and the AUC for predicting clinical disease activity was 0.83 (compared with r ¼ .75 and AUC ¼ 0.90 for the full mHI-CD). The CD DA-VAS was weakly correlated with the SES-CD (r ¼ .21; P ¼ .040), and had an AUC to predict endoscopic disease activity of 0.59 (compared with r ¼ 0.30 and AUC ¼ 0.63 for the full mHI-CD). The DA-VAS was not significantly different among patients who deteriorated, remained stable, or improved (P ¼ .12). In patients with UC (n ¼ 265) the DA-VAS had a Spearman correlation of 0.67 (P < .0001) with the pMayo, and the AUC for predicting clinical disease activity was 0.86 (compared with r ¼ .72 and AUC ¼ 0.91 for the full mHI-UC). The UC DA-VAS was also correlated with the endoscopic component of the Mayo score (r ¼ .55; P < .0001), and had an AUC to predict endoscopic disease activity of 0.79 (compared with r ¼ .60 and AUC ¼ 0.82 for the full mHI-UC). A significant difference between the DA-VAS of patients with UC that deteriorated, remained stable, or improved was observed (P ¼ .0052).
Discussion
We developed 2 questionnaires of 4 items consisting solely of PROs for remote monitoring of patients with 697  698  699  700  701  702  703  704  705  706  707  708  709  710  711  712  713  714  715  716  717  718  719  720  721  722  723  724  725  726  727  728  729  730  731  732  733  734  735  736  737  738  739  740  741  742  743  744  745  746  747  748  749  750  751  752  753  754   755  756  757  758  759  760  761  762  763  764  765  766  767  768  769  770  771  772  773  774  775  776  777  778  779  780  781  782  783  784  785  786  787  788  789  790  791  792  793  794  795  796  797  798  799  800  801  802  803  804  805  806  807  808  809  810  811  812 IBD, which can be used on mobile technology. The questionnaires were validated in a multicenter validation study and showed excellent characteristics to monitor clinical disease activity and symptom changes. As previously shown, UC clinical disease activity highly correlates with endoscopic disease activity, whereas correlation between CD symptoms and endoscopic findings is poor. 21 Although previous studies have aimed to identify PROs for disease monitoring either by adjusting existing questionnaires, 16 or by using subcomponents of existing questionnaires, 18, 19 we were able to prospectively identify PROs relevant for clinical disease monitoring and validate those in an independent cohort. Interestingly, patient-reported disease activity was shown to be an independent predictor for clinical disease activity in patients with UC and patients with CD, even after inclusion of common IBD symptoms, such as stool frequency and abdominal pain. Patient-reported disease activity alone had a comparable performance with the complete mHI in both CD and UC for detecting clinical and endoscopic activity, although responsiveness to changes in disease activity was reduced in particular in patients with CD.
A limitation of this study is the potential for recall bias in CDAI calculation. Although 7-day diary forms were sent out in advance, we did not log whether diaries were filled out daily or by recall. Additionally, in the validation cohort, optimal cutoffs of the mHI for detection of disease activity were higher than expected for CD and lower than expected for UC. This might be caused by the reduction of questionnaire items from >20 PROs to just 4, or by differences in the patient population. The validation phase of the study most accurately represents the real-life situation. Therefore, we implemented the cutoff for optimal sensitivity and specificity as observed in the validation cohort in clinical practice.
This study was not primarily designed to evaluate correlations between PROs and endoscopic healing. In atrisk patients, clinical assessments remain warranted, which may lead to further endoscopic evaluation. This tool offers an optimal screening method to monitor and evaluate disease activity in and outside of clinical practice with a high NPV. The mHIs are currently implemented in the UCLA eIBD patient app ( Supplementary  Figure 2) and automated messages are sent to a nurse coordinator when the mHI indicates disease activity. The 813  814  815  816  817  818  819  820  821  822  823  824  825  826  827  828  829  830  831  832  833  834  835  836  837  838  839  840  841  842  843  844  845  846  847  848  849  850  851  852  853  854  855  856  857  858  859  860  861  862  863  864  865  866  867  868  869  870   871  872  873  874  875  876  877  878  879  880  881  882  883  884  885  886  887  888  889  890  891  892  893  894  895  896  897  898  899  900  901  902  903  904  905  906  907  908  909  910  911  912  913  914  915  916  917  918  919  920  921  922  923  924  925  926  927  928 app is currently available to patients treated at the UCLA Center for IBD and can be downloaded in iOS or Android by searching for "UCLA eIBD." The calculation of the mHI is complex. However, simplifying the score would most likely result in loss of accuracy. Because the index is meant to be automated and implemented on digital platforms, we believe that using the more complex calculations is justified.
Cloud-based health technologies are predicted to revolutionize care delivery and patient engagement. Patients can participate in their care by signaling meaningful health outcomes during year-round monitoring. Barriers for more widespread implementation of mHealth in IBD care include policies affecting reimbursement and regulatory requirements, 22 and privacy and security concerns. 1 In summary, we developed the mHI-CD and mHI-UC for remote monitoring of patients with CD and patients with UC. The scores are specifically designed for implementation on a mobile application and are currently available to patients with IBD treated at the UCLA Center for IBD. Prospective randomized studies need to assess the effect of remote monitoring on disease control, quality of life, patient satisfaction, and health care costs.
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